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Abstract: The fast developmental pace and 
widespread use of mobile technology and the 
internet mean that smartphone-based m-health 
(mobile health) applications (apps) have huge 
potential to further expand the reach of and access 
to drug-related health services towards a common 
goal of ensuring a healthier Europe. However, 
m-health for drug users and for health professionals 
in the field of drugs is still in its infancy and poorly 
documented at European Union (EU) level.
The aim of this scoping study was therefore to 
carry out a first exploration of available smartphone 
applications in the drugs field within a European 
and global context. It explored the range of m-health 
applications available to users and professionals 
seeking information, support and advice in a wide 
range of EU languages.
The systematic search of drug-related smartphone 
applications identified a total of 67 applications 
across the three main app stores. The identified 
m-health applications apply various technologies 
ranging from simple text-based content display 
to more advanced interactive functions such as 
video transmission, geo-tagging functions and 
automated personalised feedback. Based on the 
main objectives, content and target end-users of the 
67 identified apps, three main groups of drug-related 
m-health applications emerged: apps that aim to 
disseminate drug-related information and advice, 
apps that provide interventions and support for drug 
users and apps for capacity building among health 
professionals. Most m-health apps address risk 
behaviour associated with drugs in general or drug 
use in specific settings (e.g. nightlife settings). Some 
drug-specific apps are available for more commonly 
used drugs such as cannabis and cocaine.
A number of challenges for users, app developers 
and policymakers were identified in this scoping 
study. The lack of scientific evaluations of drug-
related m-health interventions is concerning 
considering the increasing interest in and availability 
of such apps. Additionally, the lack of quality control 
of the content of these apps available to EU citizens, 
with no age limits, remains to be addressed. Global 
differences in therapeutic approaches used in the 
identified apps were apparent, especially between 
the United States and Europe, and this raises 
questions about the cross-cultural relevance of 
m-health applications. At the same time, the impact 
of the new EU General Data Protection Regulation 
may be of particular relevance in a context of fast 
global development of drug-related m-health apps 
available to EU citizens.
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I  Introduction
I  What are e-health and m-health?
Digital healthcare, also known as e-health, refers in general to 
tools and services that use information and communication 
technologies (ICTs) to improve prevention, diagnosis, 
treatment, monitoring and management of health. Optimised 
digital healthcare has the potential both to improve access 
to and quality of care and to increase the efficiency of the 
health sector and national healthcare systems. The European 
Commission recognises the potential of e-health and its 
applications to improve health outcomes. Its e-health Action 
Plan 2012-2020 provides a roadmap to ‘empower patients and 
healthcare workers, to link up devices and technologies, and 
to invest in research focused on personalised medicine in the 
future. This means providing smarter, safer and more patient-
centred health services through the use of digital technologies’ 
(European Commission, 2012).
The term ‘e-health’ is used to describe the interaction between 
patients and healthcare providers, the transmission of 
patient data between healthcare providers and peer-to-peer 
communication among patients and health professionals. 
Potential e-health services include making electronic health 
records available to professionals and patients across the 
European Union (EU), e-prescribing, virtual healthcare teams 
and telemedicine (medical consultations via the internet or 
using mobile health applications on smartphones;  
see Table 1). Given the fast-growing uptake of tablets and 
smartphones, the EU’s e-health Action Plan also includes a 
special focus on mobile health and encourages Member States 
to make further use of digital solutions within and across 
national healthcare systems.
Mobile health, or m-health, is a component of e-health. The 
Global Observatory for eHealth defines m-health as ‘medical 
and public health practice supported by mobile devices, such 
as mobile phones, tablets, portable patient monitoring devices, 
personal digital assistants and other wireless devices’ (WHO, 
2011). m-Health is thus a general term that describes the use 
of wireless technology in the delivery of medical care (Patrick 
et al., 2008; Fjeldsoe et al., 2009).
For the most part, m-health technology makes use of the 
core utility of voice and short messaging service (SMS) of 
mobile devices, be they smartphones or tablets. It also uses 
more complex functionalities and information-sharing utilities 
through applications (apps), which draw on a variety of data 
sources such as remote web servers, the Global Positioning 
System, internal sensors (acceleration, gyroscope, barometer) 
and additional peripheral wearable devices connected via 
Bluetooth technology, such as smartwatches and electronic 
wristbands.
The wide public adoption of mobile phones and smartphones 
connecting to the internet is key to the proliferation of 
m-health. The internet plays a fundamental role as it is both 
a major communication channel and a source of data for 
m-health technologies. In the EU, more than 80 % of those 
aged 16-74 used the internet in 2016, with mobile phones and 
TABLE 1
e-Health technologies and functionality (adapted from Pagliari et al., 2005)
e-Health technology Functionality
Electronic health records Communication of patient data between healthcare professionals
Computerised professional requests Requesting diagnostic tests and treatments electronically, receiving results electronically
e-Prescribing Access to prescribing options, electronic transmission of prescriptions from doctors to 
pharmacists, etc.
Clinical decision support system Providing information electronically about protocols and standards for healthcare 
professionals to facilitate diagnosis and treatment
Telemedicine Diagnosis and treatments at a distance, including telemonitoring of patients’ functions
Consumer health informatics Use of electronic resources on healthcare topics by patients and other individuals, for example 
decision aids for patients facing difficult choices, public information and educational tools 
for specific clinical groups, clinician-patient communication tools, rating information on the 
quality of professional services, and ‘virtual’ health communities
Health knowledge management Fast access to concise treatment relevant information, for example an overview of the results 
of a recent meta-analysis on opioid substitution treatment, best practice guidelines or 
epidemiological tracking
Virtual healthcare teams Connecting electronically inter-professional healthcare workers who collaborate and share 
information on patients
m-Health Includes the use of mobile devices in collecting aggregate and patient-level health data, 
providing healthcare information to practitioners, researchers and patients, real-time 
monitoring of patients’ vital signs and direct provision of care (via mobile telemedicine)
Technologies to analyse and use big data Powerful computing and data management technologies to handle large amounts of 
heterogeneous data
Health informatics/healthcare information systems Software solutions for appointment scheduling, patient data management, work schedule 
management and other administrative tasks
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smartphones as the devices most frequently used to surf the 
internet (Eurostat, 2017). These findings highlight the strategic 
significance of new mobile technologies in the provision of 
healthcare interventions to individuals at risk and professionals 
alike. In fact, market research foresees that global revenues for 
m-health will reach nearly USD 46 billion (EUR 39 billion) in 
2018 (see Figure 1), with Europe amongst the largest m-health 
markets worldwide (BCC Research, 2017).
I  What are drug-related e-health and m-health interventions, and do they work?
Digital methods of delivering drug-related interventions or 
disseminating drug-related information initially relied on 
desktop and laptop-based devices, with content accessible 
on computers via web browsers connected to the internet. 
A variety of different websites support people using licit and 
illicit substances. They range from the purely informational to 
the fully automatised online treatment programmes. Desktop-
based drug-related treatment interventions are structured drug 
treatment interventions, offered on and communicated over 
the internet, possibly involving therapist interaction. They may 
be specifically designed for a desktop platform or adapted to 
desktop use from existing interventions elsewhere. Treatment 
interventions tend to have a defined schedule and time frame, 
with more advanced interventions including psychosocial 
intervention approaches such as cognitive behavioural therapy 
(CBT), motivational interviewing and relapse prevention theory. 
If websites incorporate responsive design features, then their 
content automatically adapts to the layout of smartphone 
screens. This functionality allows users to access desktop-
based drug-related interventions through their smartphones. 
Systematic reviews of traditional desktop-based interventions 
delivered via the internet conclude that these are effective in 
achieving positive behavioural changes in people with alcohol, 
tobacco and other substance-related problems (Gainsbury and 
Blaszczynski, 2011; Hoch et al., 2016; Quaglio and Esposito, 
2017). However, the systematic reviews also highlight that, 
owing to the variety of programmes, features and target groups, 
a stronger research base is needed to establish a conclusive 
evidence base. In this context, the European Monitoring Centre 
for Drugs and Drug Addiction (EMCDDA) has published two 
reports on the availability and effectiveness of desktop-based 
interventions, such as internet-based drug treatment for 
problem cannabis use (see EMCDDA 2009, 2014).
The transition to mobile technologies in the delivery of drug-
related interventions took off with the introduction of SMS. 
SMS-based interventions involve daily or weekly motivational 
text messages to support behavioural change, computer-
generated personalised assessment and automated feedback 
on drug consumption and well-being. These interventions 
may be delivered in conjunction with traditional face-to-face 
therapies or desktop-based internet treatment interventions. 
SMS-based treatment has shown effectiveness primarily in 
aiding smoking cessation and in reducing alcohol consumption 
(Keoleian et al., 2015; Berman et al., 2016; Fowler et al., 2016; 
Kazemi et al., 2017). The research base for illicit substances 
appears to be limited. The type of technology is only one 
factor influencing the impact of internet-based interventions. 
According to Litvin et al. (2013), other moderating factors 
FIGURE 1
Predicted global revenues for m-health in 2021 (adapted 
from BCC research, 2017)
Definitions
Electronic health (e-health)
The use of emerging information and communication 
technology to improve or enable health and healthcare 
(Norman et al., 2007). e-Health technologies have three 
main overlapping functions: (1) to enable the storage, 
retrieval and transmission of data; (2) to support clinical 
decision-making; and (3) to facilitate remote care.
Mobile health (m-health)
Medical and public health practices, health information 
dissemination and patient data collection supported by 
mobile devices such as smartphones, patient monitoring 
devices, personal digital assistants and other wireless de-
vices (WHO, 2011). m-Health is a subsegment of e-health.
Mobile application (mobile app)
A type of software programme designed to run on mobile 
devices such as smartphones and tablets; commonly 
referred to as an ‘app’.
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include the nature of the content (static or dynamic) and 
level of tailoring; contact with clinicians and peers; the 
theoretical framework; attrition, duration and exposure to 
the interventions; and the setting and location where the 
intervention is received by the user.
A significant advance in portable and mobile phone technology 
occurred with the development and widespread public 
adoption of smartphones. Smartphones are mobile phones 
with an integrated computer and include features not originally 
associated with mobile phones, such as an operating system, 
touchscreens, web browsing and the ability to run software 
applications. These technological mobile features enabled 
the application and delivery of a range of advanced digital 
health drug-related interventions, such as treatment, patient 
monitoring and supervision, drug prevention, harm reduction 
services, digital outreach and drug-related e-learning. 
Furthermore, digital interventions can be applied on a wide 
range of ‘smart’ mobile devices beyond phones, for example 
tablets and wearable devices such as smartwatches and 
electronic wristbands.
Smartphone-based m-health applications, in particular, provide 
new possibilities for health practices in the drugs field, such as 
the provision of location-based services via geo-tagging. Geo-
tagging is the process of adding geographical identification 
metadata to media sources, including not only photographs 
and videos but also websites and apps. This feature allows 
app users to locate geo-tagged service points, in this case 
nearby peers or healthcare professionals and institutions 
in case of emergency. One novel feature of m-health is the 
just-in-time adaptive intervention (Nahum-Shani et al., 2016). 
These mobile interventions seek to adapt to a user’s emotional, 
social and physical state to prevent negative health outcomes 
arising, for example, from high-risk drug use, and to promote 
healthy behaviours via users’ smartphones or smartwatches. 
Researchers in Europe, for instance, are currently 
contemplating the development of low-cost electronic 
wristbands for drug users at high risk of overdose (e.g. heroin 
users). The wristbands can monitor heart rate and transmit 
an emergency signal to nearby health providers or relatives, 
alerting them to a potential drug overdose. Geo-tagging and 
just-in-time adaptive interventions are just two examples 
revealing the potential of m-health technologies as a tool to 
support drug users and professionals in the field.
To date, the number of studies assessing the effectiveness 
of smartphone m-health interventions for substance users 
remains limited. Three recent systematic reviews (Berman et 
al., 2016; Fowler et al., 2016; Kazemi et al., 2017) of m-health 
interventions in substance use have found 26 studies, of which 
only four involved smartphone applications (Gajecki et al., 
2014; Gustafson et al., 2014; Witkiewitz et al., 2014; Gonzalez 
and Dulin, 2015). The four studies involving smartphone 
m-health interventions, as detailed below, were randomised 
control trials assessing the impact of particular applications 
on high-risk alcohol use. The most recent one, by Gonzalez 
and Dulin (2015), compared the effects of a smartphone 
application intervention and a web-based intervention, for 
six weeks, among 54 adults with diagnosed alcohol use 
disorders. The results showed a large increase in daily hours 
of abstinence among the app group, while both interventions 
resulted in significant reductions in the number of drinks 
consumed per week. Gustafson et al. (2014) evaluated the 
use of a smartphone application for a period of eight months 
among 349 adults with alcohol use disorders. The experimental 
group used the application-based intervention in combination 
with treatment as usual, while the control group received 
only treatment as usual. The results showed that the average 
number of days on which high-risk drinking occurred was 
lower, and likelihood of consistent abstinence higher, in the 
experimental group than in the control group. Only one study 
reported an overall negative result. Gajecki et al. (2014), who 
tested an existing application on hazardous drinking behaviour 
among university students, reported that the number of 
drinking occasions increased among male student app users.
Overall, although the range of existing smartphone-based 
interventions for substance users available for downloading 
appears to be vast, the number that have been empirically 
tested remains worryingly low. A qualitative review of 
smartphone apps for drinking behaviour found over 700 
apps on the iTunes platform alone (Cohn et al., 2011). 
However, it was found that the majority focused on facilitating 
alcohol consumption through drinking games, and only 
one was intervention oriented. Among the latter, three of 
the four principles of effective alcohol-related treatments 
were represented, but about half relied on self-monitoring 
techniques, which constitute only a small part of an effective 
treatment. The review also found that roughly 10 % of the 
intervention apps could not be categorised as empirically 
based or potentially effective. Although several were found to 
be based on empirical principles, no review data were provided 
to inform the user as to whether or not the apps had been 
empirically tested.
A similar qualitative review of smoking cessation smartphone 
apps found 98 apps on download platforms for the most 
common smartphone operating systems, iOS and Android 
(Abroms et al., 2013). Although some apps were found to 
have useful attributes, such as interactive features or being 
specific to behaviours such as smoking, the vast majority of 
them lacked basic evidence-based practices. Potentially useful 
features that were largely omitted included referral to a quit 
smoking line (no apps) and recommendation of approved 
medications (4.1 % of apps). Only a few apps were found 
to include text alerts, and no apps included text messaging, 
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the most tested and proven application of mobile phones for 
smoking cessation (Whittaker et al., 2016).
An Australian study investigated the content of smartphone 
apps for addiction recovery and the reviews reported by 
users on their download platforms (Savic et al., 2013). Out 
of 87 apps, only six focused on illicit drugs, with the vast 
majority (77 %) focusing on addiction in general or alcohol 
disorders in particular. The study found that apps typically 
provided information on recovery, as well as content to 
enhance motivation and promote social support, and tools to 
monitor progress. Reviews by users commented on how the 
apps informed them, kept them focused, inspired them and 
connected them with other people and groups. Nevertheless, 
no information on their outcomes or effectiveness in reducing 
addictive behaviours was available. It should be noted that 
existing published content analyses of smartphone-related 
m-health interventions relate to apps developed either in the 
United States or in the English language, which may have 
implications for the cross-cultural validity of interventions and 
their geographical relevance. Another important issue that 
remains to be addressed in a systematic and coordinated 
manner by m-health professionals and developers, and 
European policymakers, is the lack of clear guidelines 
addressing the ethical challenges associated with m-health 
interventions in the drugs field relating to the transmission of 
personal data, data protection and user privacy.
The fast developmental pace and widespread usage of mobile 
technology and the internet, mean that m-health smartphone 
apps have great potential to further expand the reach of and 
access to drug-related healthcare services towards a common 
goal of ensuring a healthier Europe. However, drug-related 
m-health practices and interventions for either users or 
professionals remain in their infancy and are as yet poorly 
documented at EU level.
I  Objectives
This research sought to carry out a first exploration of available 
drug-related m-health apps in Europe. It explores the different 
apps available to users and health professionals in 16 
European languages. Owing to its exploratory nature, and the 
possible wide range of apps in multiple languages, the study 
was intended not as a rigorous scientific content analysis but 
rather as an exploration of the range of drug-related m-health 
apps available in the EU as well as their primary objectives 
and target end-users. An exploratory exercise of this nature 
provides the opportunity to identify in the first instance relevant 
apps that may be analysed for content in future follow-up 
studies. It also enables an informed discussion on the current 
limitations and challenges in the field. Finally, it highlights 
implications for app developers, researchers and European 
decision-makers in relation to research gaps, quality standards, 
ethical concerns and investment priorities.
I  Methods
The approach used in this scoping study involved a systematic 
search across the main mobile application stores — Google 
Play (Android), App store (iOS) and Microsoft store (Android) 
— between 23 May and 16 June 2017. Keywords related to 
drugs, health interventions and intervention settings were used 
as initial search terms (see Figure 2), and the apps found were 
screened for relevance. All apps with content related to illicit 
drug use were included. Apps tailored exclusively to the use of 
licit substances, such as alcohol and tobacco, were excluded.
Based on the frequency of success to generate a high yield of 
available apps, key terms were selected for the second round 
of searches. These included drug, addiction, recovery, cocaine, 
cannabis, amphetamines, heroin, Narcotics Anonymous, 
prevention and nightlife. These key terms were translated into 
the following European languages: Croatian, Danish, Dutch, 
French, Finnish, German, Greek, Hungarian, Italian, Lithuanian, 
Norwegian, Portuguese, Serbian, Spanish and Swedish. The 
study excluded 10 official languages of the EU owing to the 
lack of access. Unpopular apps — downloaded by users fewer 
than 50 times — were excluded from the study; an exception 
was made for two apps that, although downloaded fewer than 
50 times, had been recently launched (less than four months 
before the initial search).
A total of 98 apps met the inclusion criteria, resulting in a 
working sample of 67 apps after removal of duplicates. App 
content was then analysed by two researchers and coded and 
grouped according to type of intervention, primary objectives of 
the application and application features such as target group, 
language, country of origin, developer affiliation, content and 
intervention background. The researchers drew on the apps’ 
descriptive information available at the app stores. In the 
event of uncertainty, the app was downloaded, installed on a 
smartphone and analysed by the researchers.
The chosen methodology encompasses limitations that need 
to be considered when interpreting the data. Search engines 
work with algorithms that are devised for particular platforms 
with particular goals in mind. The algorithm of search engines 
within app stores is very different from that of a systematic 
search in a scientific search engine such as PubMed. For 
example, app stores’ search engines do not allow for the use 
of the ‘AND’ command, which may render some apps more 
difficult to find. Furthermore, inconsistent search results were 
observed during the search period, possibly as a result of 
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changes to the terms’ characteristics controlled by the app 
stores or their search engines. To ensure the consistency of 
results, searches were carried out multiple times.
Another limitation concerns the number of app downloads: 
only the Android app store provided the number of downloads 
for each app. In addition, the number of downloads is merely 
indicative as it is possible that apps are downloaded but not 
used, or that the download figures are not accurately reported 
by the app store.
Geo-blocking was another concern. It is possible that some 
searches were geo-blocked, most likely those in languages 
not corresponding to the country where the search took 
place. For the present study, the search took place primarily 
in Switzerland, but also in Portugal, Finland and Lithuania. 
Therefore, it cannot be assumed that a similar systematic 
search will yield the same results if carried out in different 
EU countries. Furthermore, because of the large number of 
languages used in the search, inter-coder reliability analysis 
was not feasible; hence the homogeneity of content coding 
between independent coders cannot be guaranteed.
Finally, because this exercise is intended as an exploratory 
investigation of available m-health apps, no quality assessment 
was performed on the content of the apps. Future studies 
Search using 3 main app stores:
1. Google Play
2. iTune App
3. Microsoft App
Apps reviewed between 23 May
and 16 June, 2017
Information on keywords identied
General terms: drugs,
addiction, self-help, treatment,
therapy, harm reduction,
recovery
Drug-specic terms: amphetamine,
cannabis/pot/hash/hemp, cocaine,
heroin, methamphetamine/crystal meth,
MDMA/ecstasy/XTC, GHB/GBL, LSD,
mushrooms, NPS/legal highs/research
chemicals/mephedrone/methylone,
ketamine
Setting-specic terms:
prevention, nightlife, narcotics
anonymous, MSM/gay
Initial search terms used to
screen apps for relevance
Second round of search
Key terms used: drug, addiction, recovery, cocaine,
cannabis, amphetamines, heroin, narcotics anonymous,
nightlife, prevention
Key terms translated into multiple languages to maximise search
Apps with low popularity (< 50 downloads) determined by the stores were excluded
Note: special cases of recently published apps with < 50 downloads were included
Inclusion: any apps related to drug use
Exclusion: if the apps were used for
tobacco only or alcohol only
Total: n = 67
apps identied
FIGURE 2
Methods flow chart
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should include a minimum quality assessment examining the 
usability, evidence and relevance of app content to enhance 
the potential use of findings.
I  Results
The systematic search for drug-related smartphone apps 
resulted in a set of 67 apps: 59 from the Google app store, 
37 from the iTunes App Store (30 duplicates available in both 
stores were removed) and two from the Microsoft App Store 
(one duplicate was removed).
I  Background information on drug-related m-health apps
Country of origin
The vast majority of apps were devised in the United States  
(n = 33) and Europe (n = 26), with only eight originating from 
other parts of the world (see Figure 3). In Europe, the United 
Kingdom (n = 7) and Germany (n = 6) take the lead, together 
accounting for half of the drug-related m-health apps (Figure 4).
Language
For the most part, the app language reflects its country of 
origin, with the large majority of drug-related m-health apps 
providing content in English (n = 47). Of these, only one 
offered additional languages to English (Spanish, Portuguese 
and other, non-European, languages). Other m-health apps 
provided content in German, French, Spanish, Dutch and 
Italian (Figure 5).
Target group
The target end-user of drug-related m-health apps is difficult 
to ascertain as it depends on the content and purpose of each 
app. For example, apps that provide extensive drug-related 
information on the effects and harms of drug use may be of 
interest not only to drug users but also to parents and relatives, 
health professionals and other interested members of the 
public.
As illustrated in Figure 6, most apps provided content related 
to drugs, drug addiction and drug-related addictive behaviour 
in general. Only a small number focused on one specific drug 
(e.g. cannabis or cocaine), possibly targeting users seeking 
support in reducing harms associated with the use of specific 
substances. However, some apps were clearly catering for 
particular groups such as partygoers, men who have sex with 
men (MSM) using drugs and abstinent or recovering drug 
users. A small number were directed at health professionals 
working in the drugs field.
FIGURE 3
Origin of drug-related m-health apps (N = 67)
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FIGURE 4
Country of origin of the European drug-related apps  
(N = 26)
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FIGURE 5
Language of drug-related m-health apps (N = 67) 
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Cost to users
The majority of apps (n = 59) can be downloaded free of 
charge with no subsequent costs to users. Only eight apps 
involve costs. In four cases direct costs are payable at the 
time of download (ranging from EUR 1 to 4). The other four 
charge for advanced functions only, that is optional add-ons 
to the basic functions of the app. Advanced functions include 
individualised feedback message (costs ranging from EUR 1 
to 12) and assistance from an addiction professional (costs 
approximately EUR 52). These charges are applied only 
when services are activated. Three apps with associated 
costs originate from Europe (Germany, Italy and the United 
Kingdom), four from the United States and one from India.
It is a common strategy for app distributors to make their apps 
and all contents freely available, and to introduce charges only 
when the app becomes popular and reaches a high number of 
downloads. Sometimes app distributors introduce in-app costs 
in an updated version of the app. However, the drug-related 
apps under examination here do not appear to have yet been 
affected by these commercial strategies.
I  Main groups of drug-related m-health apps
Based on the main objectives, content and target end-users 
of the 67 identified apps, three main groups of drug-related 
m-health applications emerge. The first group comprises 
apps that focus primarily on the dissemination of drug-related 
information and contain drug glossaries and health-related 
information with harm reduction advice targeted at drug 
users in nightlife settings (see ‘Dissemination of drug-related 
information through m-health apps’). The second group of apps 
are interventions aimed at raising awareness of users’ own 
drug consumption, reducing drug use or supporting abstinence 
and recovery from drugs using, for example, drug consumption 
trackers, automated feedback on personal drug consumption, 
direct contact with counsellors, abstinence-oriented self-help 
(see ‘m-Health interventions through m-health apps’) or social 
networking-based support. The third group comprises apps that 
are primarily tools dedicated to capacity building among health 
professionals in the drugs field (see ‘m-Health tools for capacity 
building among health professionals in the drugs field’).
Thus, drug-related m-health apps appear to be positioned 
along a continuum between dissemination of drug-related 
information and advice, interventions and support for drug 
FIGURE 6
Three main groups of m-health apps based on primary objectives  
Information 
dissemination
Interventions Capacity 
building
Generic drug
glossaries and
drug proles
Targeted harm
reduction
information and 
advice
Connecting to
drug services
and
professionals
Personalised
automated
feedback
Drug consumption
trackers and
diaries
Recovery-oriented
self-help apps
Social network-
based recovery
support apps
Apps for
professionals
TABLE 2
m-Health apps providing primarily drug-related information
App name Main language Country of origin Developer category Android installations (1) With costs
Drogas Spanish Spain Private individual h No
Drogen — Lexikon PRO German Germany Private individual c Yes
DrogoQuiz Spanish Spain NGO c No
Drug Effects Guide & 
Quiz Game
English United States Private company f No
GRC Drogues French Canada Governmental 
organisation
e No
Informação sobre 
Droga
Portuguese Unknown Private individual b No
Overcoming Addiction+ English United States Private individual N/A Yes
Meth Ice English India Private individual N/A No
(1) a = 50-100, b = 100-500, c = 500-1 000, d = 1 000-5 000, e = 5 000-10 000, f = 10 000-50 000, g = 50 000-100 000, h = 100 000-500 000.  
N/A, not applicable; NGO, non-governmental organisation.
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users and tools for professionals (see Figure 6). Similarly, the 
various apps along this continuum target different end-users, 
ranging from groups among the lay public, such as relatives of 
drug users or teachers, to current active drug users, individuals 
in recovery and health professionals in the drugs field.
Dissemination of drug-related information through 
m-health apps
The first group of m-health apps identified in this study 
includes applications that aim primarily at disseminating 
information on the pharmacology, effects and health risks 
associated with various psychoactive substances. Most of 
these apps contain general information on drugs and use a 
similar content style to available online resources such as the 
EMCDDA’s drug profiles or drug-specific Wikipedia pages. 
Some of these apps offer knowledge tests about substances 
and their effects, through which users can expand their 
knowledge on the risks and harms associated with drugs 
(Table 2). An example is the Spanish app ‘Drogas’, which 
provides drug profiles compiled from online encyclopaedias 
and professional websites and has been downloaded more 
than 100 000 times. A number of these apps were developed 
by individuals about whose professional background and 
expertise little or no information is provided, leading to 
concerns about the reliability of the information offered to 
users and the likelihood of the app being kept up to date. This 
is of real concern considering the number of rapidly appearing 
new psychoactive substances (NPS) on the market and the 
associated harms.
A subgroup of these applications is targeted primarily at 
partygoers and recreational drug users. These apps adopt a 
harm reduction approach, with a focus on informing users 
in these setting of the health risks associated with drug 
use (Table 3). These apps are mostly developed by nightlife 
prevention organisations. For example, the French app 
TABLE 3
m-Health apps providing drug-related information and harm reduction advice for users in nightlife settings
App name Main language Country of origin Developer category Android installations (1) With costs
KnowDrugs English United States NGO (nightlife) d No
Psychoactif French France NGO (nightlife) c No
Techno+ French France NGO (nightlife) d No
Redalert Dutch Netherlands Research institute e No
Dance Safe Mobile English United States NGO (nightlife) e No
Tripsit English Not available Not available f No
(1) a = 50-100, b = 100-500, c = 500-1 000, d = 1 000-5 000, e = 5 000-10 000, f = 10 000-50 000, g = 50 000-100 000, h = 100 000-500 000.  
NGO, non-governmental organisation.
TABLE 4
m-Health apps connecting users to healthcare providers
App name Main language Country of origin Developer category Android installations (1) With costs
About Addiction and 
Health
English United States NGO (prevention) a No
Beratungs-stellen OÖ German Austria Private organisation a No
Bridge to Sobriety! English United States NGO (treatment) b No
Crystal-App German Germany NGO (prevention) c No
Drug & Alcohol 
Helpline
English Canada NGO N/A No
Drug Addiction English United States Private individual f No
Mindzone German Germany NGO (nightlife) d No
Quit Porn/Drug/Food 
Addiction
German United States Private company h Yes
Rehabs Finder English United States Private individual N/A No
Right Path Addiction 
Centers
English United States NGO (treatment) a No
Say No to Drugs English United States Private individual/
academia
c No
(1) a = 50-100, b = 100-500, c = 500-1 000, d = 1 000-5 000, e = 5 000-10 000, f = 10 000-50 000, g = 50 000-100 000, h = 100 000-500 000.  
N/A, not applicable; NGO, non-governmental organisation.
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‘Techno+’, developed by the nightlife organisation of the same 
name, and downloaded between 5 000 and 10 000 times 
through Google Play, not only provides information on safer 
use of party drugs, but also allows users to check the potential 
risks of multiple drug use by clicking on corresponding 
drug use combinations. Another example is the Dutch app 
‘Redalert’, which provides information and alerts on drug 
checking (also known as pill testing) and communicates 
safer drug-using behaviours through the app. It provides 
information on tablets and powders with high concentrations 
of psychoactive substances, or those containing harmful 
adulterants identified through its drug-checking services. 
This app has been developed by the Dutch research institute 
Trimbos and has also been downloaded between 5 000 and 
10 000 times.
m-Health interventions through m-health apps
The largest group of m-health applications identified in this 
scoping exercise is applications that provide drug-related 
interventions aimed at raising drug users’ awareness of 
their own drug consumption with the goal of reducing drug 
consumption or drug-related risk behaviours, and also 
some apps that provide supportive in-built tools to promote 
reduction of or recovery from drug use. For example, some 
apps aim at connecting users with health professionals via 
built-in encrypted messaging systems and facilitating access 
to drug services through geographical information on nearby 
health professionals and treatment services (Table 4). Most 
of these originate in the United States or Canada and were 
developed by non-governmental organisations (NGOs) with 
a focus on drug-related prevention, treatment and helplines 
(Table 4). The ‘Mindzone’ app, developed by a German 
prevention organisation, targets primarily partygoers and 
offers counselling services with prevention and harm reduction 
professionals over a secure connection as well as contact 
information for health services in close geographical proximity 
based on the users’ smartphone location.
A few m-health apps were developed to provide personalised 
automated feedback on users’ own drug use levels as a health 
intervention to prevent or reduce drug use. Personalised 
feedback is generated through screening tools such as 
the Drug Use Disorder Identification Test, or other large 
drug-related information databases. These apps provide 
individualised feedback on the risk levels associated with 
patterns of use of specific drugs. They also attempt to adjust 
perceptions of drug use by running a comparison regarding 
how much a particular drug — such as cannabis, cocaine, 
mephedrone or MDMA — is used by peers of the same 
demographic group. The comparative approach appears to 
be inspired by the ‘social norms’ approach, which has gained 
increasing attention as a prevention intervention. Social norms 
interventions have been successful in reducing alcohol and 
tobacco use in college and high school populations (Berkowitz, 
2005). According to the social norms theory, individuals 
incorrectly perceive the attitudes and/or behaviours of peers 
and other community members in certain situations to be 
different from their own. This misperception of norms (e.g. my 
peers smoke a lot of cannabis) leads to increased consumption 
to become closer to the misperceived norm. Social norms 
theory-based interventions aim to correct misperceptions by 
revealing the actual, healthier norm. This has a beneficial effect 
on most individuals, who will either reduce their participation 
in potentially problematic behaviour or feel encouraged to 
engage in protective, healthier behaviours. Perception of 
norms is a key element of comprehensive evidence-based 
prevention interventions, yet there is no evidence base for its 
effectiveness as a stand-alone practice. Five apps that use this 
approach were identified (Table 5). For example, ‘Drugsmeter 
Mephedrone’ anonymously assesses the user’s mephedrone 
use patterns and standardises the results based on medical 
and family histories. It compares individuals’ outcomes with 
those of other Global Drug Survey participants who reported 
mephedrone use in the user’s residential area. It also includes 
an optional personal drug-problem quiz to assess levels of 
mephedrone dependence, and makes recommendations about 
how to best reduce its use. It provides information regarding 
TABLE 5
m-Health apps providing personalised automated feedback
App name Main language Country of origin Developer category Android installations (1) With costs
Drugsmeter Cannabis English United Kingdom Private company f No
Drugsmeter Cocaine English United Kingdom Private company e No
Drugsmeter MDMA/
GHB/GBL
English United Kingdom Private company e No
Drugsmeter 
Mephedrone
English United Kingdom Private company e No
Substance Use & 
Addiction
English United States Private individual b No
(1) a = 50-100, b = 100-500, c = 500-1 000, d = 1 000-5 000, e = 5 000-10 000, f = 10 000-50 000, g = 50 000-100 000, h = 100 000-500 000. 
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safer mephedrone use, mephedrone and driving or gender-
specific safer sex advice in the context of chemsex.
More sophisticated drug-related interventions delivered 
via apps contain drug consumption trackers or diaries to 
monitor use and set goals towards reduction in drug use or 
abstinence (Table 6). For example, the ‘Stop cannabis’ app, 
developed by the University of Geneva in Switzerland, uses a 
method similar to the empirically evaluated online desktop-
based cannabis intervention ‘Quit the Shit’ (Tossmann et al., 
2011). The Swiss app allows users to set their own cannabis 
consumption goals, enter information about their daily drug 
consumption patterns, take note of particular drug-related 
events in the diary (e.g. cravings), receive personalised and 
automated motivational messages or advice and receive 
automatically produced achievement reports. Another example 
is the ‘IMQuit’ app, which allows users to log data on their 
drug consumption and drug use behaviour (for several drugs), 
enabling them to monitor their own patterns. It includes 
machine learning algorithms that analyse users’ behavioural 
patterns and provide feedback to support relapse prevention 
or reduce occurrence of new consumption patterns. The app 
is designed for patients in drug treatment and allows the 
attending healthcare professionals or supervisors to have 
access to the patient’s consumption record through a website 
dashboard. This app has been downloaded between 500 000 
and 1 000 000 times — it is by far the most downloaded app in 
this category.
The ‘Ralli Recovery’ app combines drug use tracking with social 
media functions that invite friends and relatives to participate 
and support users in their effort to reduce drug use. Two apps 
in this category, ‘Addiction Tracker (Colsner)’ and ‘Schluss mit 
Sucht’, involve in-app costs ranging between EUR 1.50 and 
2.50. Although these apps are free to download, more complex 
functionalities can be optionally activated at a cost.
Interestingly, a number of apps have been primarily developed 
to support recovery from drugs through abstinence-oriented 
self-help tools. These have nearly all been developed in 
the United States by either private companies or recovery-
oriented organisations such as Narcotics Anonymous (NA) 
(Table 7). One of the most downloaded apps developed 
by Narcotics Anonymous groups is the ‘NA 12 Steps App’ 
(50 000-100 000 downloads). This app aims at supporting NA 
members in traditional NA therapeutic processes and social 
support groups that facilitate peer support and the sharing 
of experiences to maintain abstinence. Another example 
of an abstinence- or recovery-focused self-help app is ‘No 
More! Quit your Addictions’, which has features that allow 
users to count their abstinence days, receive motivational 
quotes and congratulatory messages on their achievements 
and customise in-app shortcuts to instantly access a trusted 
person or community website for social support. The app 
‘Addiction AVERT’ provides relapse prevention techniques 
based on negative reinforcement: it supports individuals 
to challenge cravings by bringing up associated negative 
events and situations that may occur with continued use of 
drugs. ‘Addiction AVERT’ can be customised to help motivate 
an individual’s personal recovery programme and provides 
opportunities to work with a sponsor.
TABLE 6
m-Health apps providing consumption-tracking tools
App name Main language Country of origin Developer category Android installations (1) With costs
Addiction Tracker 
(Colsner)
English India Private company d Yes
Addiction Tracker 
(Etilox)
English India Private company b No
Addiction zero English United States Private company N/A No
Arud Konsum-
tagebuch
German Switzerland NGO (treatment) b No
C:KYL (Chems: Know 
Your Limit)
German Germany Private individual a No
IMQuit - Quit addiction English United States Private company h No
Checkpoint C German Germany NGO (treatment) b No
No Drugs Calendar English United States Private company N/A No
Quit Cannabis English United Kingdom Private company f Yes
Ralli Recovery English United States Private company N/A No
Schluss mit Sucht German Germany Private company f Yes
Stop cannabis French Switzerland Research institute f No
7 day challenge Dutch The Netherlands NGO N/A No
(1) a = 50-100, b = 100-500, c = 500-1 000, d = 1 000-5 000, e = 5 000-10 000, f = 10 000-50 000, g = 50 000-100 000, h = 100 000-500 000.  
N/A, not applicable; NGO, non-governmental organisation.
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Our scoping exercise on drug-related m-health apps found 
two apps that foster an online social network approach for 
drug users who are attempting to reduce or in recovery from 
drug use. These apps use the same approach as popular 
online social networking applications by using features such 
as adding friends, giving ‘likes’ and sharing pictures and 
events (Table 8). For example, the app ‘Mober’ allows users to 
share pictures and videos among friends so they can witness 
their progress towards abstinence. Close members of an 
individual’s online social support network can validate and 
co-sign positive achievements and alert other members of 
the social network when an individual needs support. ‘Party 
Friends’, developed by the Trimbos Institute, also aims to 
develop a network of friends, but with a focus on the Dutch 
party scene. Users can find how many virtual friends are at the 
same event and arrange for transport and accommodation. 
Additionally, users can find out about how to respond to acute 
drug-related harms. The app also features an emergency call 
button. Both apps have a relatively low volume of downloads, 
despite sufficient and attractive social media functions. Having 
to set up a new network of virtual friends alongside established 
TABLE 8
m-Health apps providing support through social networking
App name Main language Country of origin Developer category Android installations (1) With costs
Mober English United States Private company c No
Party friends English The Netherlands NFPO a No
(1) a = 50-100, b = 100-500, c = 500-1 000, d = 1 000-5 000, e = 5 000-10 000, f = 10 000-50 000, g = 50 000-100 000, h = 100 000-500 000.  
NFPO, not-for-profit organisation.
TABLE 7
m-Health apps oriented towards recovery
App name Main language Country of origin Developer category Android installations (1) With costs
Drug Addiction English United States NA organisation f No
Drug Addiction (IGT) English United States Private company d No
Field Guide to Life Pro: 
Recovery Support
English United States Private company d No
MAPconnect — 
Addiction Recovery 
Support
English United States Private company a No
Marijuana Anonymous English United States NA organisation f No
My Sober Life Pro: 
Young Adult Recovery 
Support
English United States Private company b No
NA 12 Steps App English United States NA organisation g No
NA Ireland English Ireland NA organisation b No
New2Recovery for 
Addictions
English United States Private company e No
No More! Quit your 
Addictions
English Italy Private company h Yes
PW recovery English United States Private company N/A No
Recovery from Drug 
Addiction
English United States Private company N/A No
Self Help *Just for 
today* NA
English United States NA organisation h No
Sober Time — Sobriety 
Counter
English United States Private company h No
Sober Tool English United States Private company g Yes
Addiction AVERT English United States Private company b No
Hypnosis for Addiction 
& Sober
English United States Professional person d Yes
Overcome Addictions 
Hypnosis
English United Kingdom Professional person c No
(1) a = 50-100, b = 100-500, c = 500-1 000, d = 1 000-5 000, e = 5 000-10 000, f = 10 000-50 000, g = 50 000-100 000, h = 100 000-500 000.  
N/A, not applicable; NGO, non-governmental organisation.
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popular social networking platforms may account for their 
apparent lack of success.
m-Health apps for capacity building among health 
professionals in the drugs field
Surprisingly, we found only a few apps that can assist 
professionals in the drugs field in their daily work (Table 9). 
One of these apps is the ‘NICE guidance’ app. It was developed 
by the National Institute for Health and Care Excellence 
(NICE) in the United Kingdom and features all available 
clinical guidelines, including those addressing interventions 
for drug-related problems. ‘SITDintasca’, an app from the 
Italian Society of Addiction Disorders, facilitates access to 
relevant documents, web news and events. It also runs a 
forum for professionals and experts in the field of addiction. 
The American company EMOCHA produced an app to be used 
by patients in opioid substitution treatment that acts as a 
tool for prescribers to monitor users’ adherence to treatment. 
EMOCHA’s ‘miDOT’ app uses asynchronous videos to manage 
directly observed therapy. In other words, it allows patients to 
use their smartphones’ video function to record themselves 
taking the medication. Patients can also report side effects 
or symptoms and record every dose of medication using the 
smartphone app. Clinicians can then view and manage patient 
data, communicate with patients and review their progress 
on a web interface. This m-health app for practitioners and 
patients is aimed at encouraging patient engagement and 
medication adherence.
I  Discussion
This scoping exercise identified 67 smartphone apps 
downloadable in Europe that provide different forms of drug-
related information or interventions. These apps apply different 
technologies ranging from simple text-based content display 
to advanced interactive functions such as geo-tagging, video 
transmission and automated personalised feedback. Most 
apps featured some content information on drugs, their effects 
and associated risks and harms. The majority of drug-related 
apps have more advanced functionalities that include some 
type of intervention. These range from approaches inspired 
by harm reduction and prevention interventions to more 
structured or sophisticated interventions for users aiming at 
reducing or abstaining from drug use via their smartphones or 
tablet devices. Generally, such apps were commonly developed 
by NGOs and research institutes with an established presence 
in the field of drugs and drug addiction.
I  Geographical differences in approaches
Interestingly, differences emerge in intervention approaches 
between apps originating in the United States and those from 
Europe. United States-based apps providing interventions tend 
to adopt a recovery-based approach inspired by the Alcoholics 
Anonymous approach for recovery from alcohol dependence. 
This is illustrated by the number of US m-health apps 
developed by NA groups aiming to facilitate contact between 
recovering drug users and sponsors or to provide motivational 
messages to remain abstinent.
In contrast, Europe-based apps delivering m-health 
interventions tend to adopt a preventive and harm 
reduction approach towards drug use with interventions 
rooted in established scientific approaches, such as brief 
interventions or CBT. The Swiss ‘Stop Cannabis’ application 
is a good example: it uses motivational interviewing and CBT 
approaches. This contrast between United States- and Europe-
based apps may also be reflected in target end-users. Europe-
based apps tend to cater for partygoers or recreational users 
while United States-based apps tend primarily to address 
ex-users in recovery. Similarly, Europe-based app developers 
more commonly include NGOs operating in nightlife settings or 
research institutes such as the Dutch Trimbos Institute, while 
the majority of US apps are developed by private companies. 
Differences in m-health approaches between world regions 
may also reflect historical differences in demand reduction 
traditions and policies. It may therefore be easier for Europe-
based organisations to produce content with harm reduction 
TABLE 9
m-Health apps for healthcare professionals
App name Main language Country of origin Developer category Android installations (1) With costs
Addiction 101 English South Africa Private company c No
NICE Guidance English United Kingdom Professional 
organisation
h No
miDOT English United States Private company c No
SITDintasca Italian Italy Professional 
organisation
a No
(1) a = 50-100, b = 100-500, c = 500-1 000, d = 1 000-5 000, e = 5 000-10 000, f = 10 000-50 000, g = 50 000-100 000, h = 100 000-500 000. 
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messages. For example, drug testing in nightlife settings may 
not be tolerated in other parts of the world. These differences 
raise questions on the relevance and attractiveness of 
available drug-related m-health content and interventions to 
users from different regions of the world. This is also relevant 
in the EU context, in that apps developed in one Member State 
may not be as relevant and attractive to users in other Member 
States. Language, quality and type of content, age, target user 
groups and data protection issues can be relevant factors in 
this regard.
I  Limited language coverage
All m-health apps identified in this publication can be 
downloaded by anyone geographically located in Europe. 
However, the limited number of apps in native European 
languages may constitute an important barrier to the use 
of digital intervention tools in the field of drugs and drug 
addiction. The method used in our search applied 16 
European languages in the search for apps and found that 
drug-related m-health apps were available in fewer than 10 
EU Member States languages, with searches in Scandinavian 
and Eastern European languages yielding no results. These 
findings should be interpreted carefully as it is possible 
that apps from particular Member States were geo-blocked 
to the researchers, as discussed in the Methods section. 
Nevertheless, the findings suggest that the number of apps 
available in languages other than English is limited, with apps 
in French, Dutch, German and Spanish primarily aimed at 
the dissemination of harm reduction information and advice 
among partygoers. Treatment-related m-health interventions 
supporting the reduction or abstinence from drug use are 
currently still limited in Europe, while those that are available 
have not yet documented scientific evidence of efficacy or 
effectiveness. Thus, while several apps were found to adopt 
empirically based principles in their interventions, no review 
data was provided to the user to support whether or not these 
apps have been empirically tested.
I  Drug- and setting-specific focus
Most m-health apps identified here address risk behaviour 
associated with drugs in general or drug use in specific 
settings (e.g. nightlife settings) or include drug-specific 
sections. Some drug-specific apps are available for more 
commonly used drugs such as cannabis or cocaine. However, 
we found one application that exclusively addresses NPS. As 
the number of NPS present in the European market continues 
to be significant, the development of dedicated mobile apps by 
authoritative institutions providing timely information on newly 
identified NPS and their known and potential health risks, as 
well as harm reduction features, could be an efficient way to 
reach large numbers of NPS users. National and European 
early warning systems may consider the utility of such apps for 
users and health professionals in the field. It should be noted 
that this information may already be available on websites 
accessible primarily from desktop computers, such as the 
EMCDDA Action on new drugs web page, which is publicly 
available. However, it is important that website developers 
be encouraged to apply a responsive design that allows 
web pages to change their appearance and usability to suit 
the viewing properties of mobile devices (e.g. smartphones, 
tablets).
I  Underrepresented target groups
Most apps that were identified address the information or 
intervention needs of drug users in general or, in some cases, 
more targeted groups, such as users in nightlife settings. 
However, some specific user groups were found to be currently 
underrepresented within the target groups of available drug-
related m-health apps, such as MSM engaging in chemsex and 
high-risk drug users.
Chemsex is a term often associated with the use of 
psychoactive substances within the context of sexual practices 
among MSM. Chemsex is associated with particular risk 
behaviours, such as unprotected sex and the sharing of drug 
paraphernalia, both of which increase the risk of transmission 
of infections such as HIV and hepatitis C virus. A study by the 
European Centre for Disease Prevention and Control (ECDC, 
2015) reported a proliferation of mobile dating platforms 
for MSM, which included explicit exchanges between 
users seeking chemsex. While digital outreach by health 
professionals within these apps has proven to be difficult, 
the development of separate m-health apps targeting MSM 
engaging in chemsex may be important in accessing this 
hard-to-reach group. In this scoping exercise we retrieved only 
one app specifically catering for people engaging in chemsex: 
the German ‘C:KYL’ (‘Chems: Know Your Limit’). This app 
allows users to document and track the use of drugs (such 
as poppers, GHB/GBL (gamma-hydroxybutyrate/gamma-
butyrolactone), cocaine and methamphetamine) used during 
sexual activities with partners  but does not offer any further 
harm reduction or drug consumption reduction interventions. 
Further investments are required in the development of 
relevant, attractive and scientifically sound apps for European 
MSM that include sexual health promotion, chemsex-related 
harm reduction and drug use reduction interventions.
High-risk drug users, such as heroin injectors in and out of 
treatment, may also benefit from m-health apps. A recent 
meta-analysis of internet-based interventions for illicit 
substance users (Boumparis et al., 2017) demonstrated 
that internet interventions could be effective add-ons to 
substitution treatments for this population. We found only 
one app focused on this user group: a US application that 
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helps patients in opioid substitution treatment to adhere to 
their treatment regime through daily video and text-based 
interaction with their health providers. It could be argued that 
some of the apps described in this report may address some of 
the supportive needs of former high-risk drug users in recovery. 
However, further harm reduction apps for active high-risk drug 
users could be developed that include overdose emergency 
components, such as emergency numbers, training on the use 
of naloxone emergency kits and provision of wristbands that 
monitor vital signs and automatically connect to emergency 
services in the event of overdose.
I  More m-health tools needed for health professionals
Health professionals in the field of drugs and drug addiction 
could also benefit from further development of m-health tools. 
Mobile devices may provide access to relevant clinical material 
and e-learning tools to clinicians at any time. The app from 
NICE (see ‘m-Health apps for capacity building among health 
professionals in the drugs field’) is a good example of high-
quality and accessible clinical content on smartphones and 
tablets. However, similar user-friendly mobile e-learning tools 
for European drug professionals are currently rare. Further 
developments in this area could focus on m-health tools that 
facilitate exchange of knowledge and skills between classroom 
settings and clinical practice and assist health professionals in 
reviewing and applying skills with patients. For example, Satre 
et al. (2017) developed and tested, with positive results, a 
mobile learning app for health professionals (e.g. nurses, social 
workers, medical trainees), based on the theory of planned 
behaviour, to deliver screening, brief intervention and referral 
to treatment (SBIRT), which is an effective approach to identify 
and treat individuals at risk of problem alcohol or drug use.
I  Quality challenges
As technology and interest in m-health apps in the drugs field 
is likely to grow, a number of important points need to be 
addressed. First, a large number of m-health apps containing 
drug-related information appear to be aimed at young users, 
especially partygoers. However, there is no consensus on the 
age limit that would be appropriate for such apps. For the most 
part, drug-related m-health apps do not undergo formal quality 
control and, as mentioned earlier, are not necessarily based 
on sound scientific evidence, which means that the drug-
related information and interventions they provide may cause 
unintentional harm, especially among young inexperienced 
users. Possible ways to minimise potential harms of m-health 
apps include tighter parental controls, regulation ensuring 
minimum quality control and careful screening of content for 
accreditation.
Another issue to consider is whether or not the quality 
standards and accreditation systems that are applied when 
implementing new drug-related services should also be 
applied to the development and provision of drug-related 
m-health apps and to the health providers using them. There 
are adapted standards for internet addiction counselling 
(Schaub et al., 2014) that could be tailored to the context of 
drug-related intervention apps. The recent European Minimum 
Quality Standards in Drug Demand Reduction interventions 
(Council of the European Union, 2015), adopted at EU level, 
could be updated to include minimum quality standards for 
e-health and m-health at EU level. As mentioned before, there 
is a general lack of information provided by app developers 
on clinically relevant results and evidence of safety and 
effectiveness of their product. A regulatory process could 
address this gap by carefully evaluating m-health apps, or 
requiring evidence of safety, effectiveness and ethical conduct 
before routine public distribution and clinical use (Capon et al., 
2016).
I  Concerns about data protection for EU citizens
Finally, the use of drug-related m-health apps that log 
personal information raises important ethical and legal 
considerations with regards to data storage, data ownership, 
third-party access, informed consent, privacy and personal 
data protection (Capon et al., 2016; Pisani et al., 2016). This 
is particularly relevant as the processing of personal data 
(e.g. health or drug-related data) provided in such apps 
remains obscure. For instance, there is no clear information 
on safeguards concerning data breaches and the sharing of 
personal behavioural data with third parties or government 
institutions. The EU General Data Protection Regulation 
(GDPR)(1) , adopted in April 2016, was designed to ‘harmonise 
data privacy laws across Europe, to protect and empower all 
EU citizens’ data privacy, and to reshape the way organizations 
across the region approach data privacy’ (European 
Commission, 2016).
An in-depth discussion of European data protection laws 
relevant to m-health is beyond the scope of this study. 
However, there are significant inclusions in the new EU 
Regulation that will affect personal data sharing, as in the 
case of exchange of personal health or drug-related data 
within m-health apps. Probably the most important regulatory 
change consists in the extraterritorial applicability of the GDPR 
and concerns all companies processing the personal data 
of subjects residing in the EU, regardless of the company’s 
location. As a consequence, any m-health developers located 
(1)  Regulation (EU) 2016/679 of the European Parliament and of the 
Council of 27 April 2016 on the protection of natural persons with 
regard to the processing of personal data and on the free movement of 
such data, and repealing Directive 95/46/EC (General Data Protection 
Regulation). 
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outside the EU but collecting or processing data obtained 
within the EU will have to abide by the EU GDPR. This means 
that the request for consent must be in an intelligible and 
easily accessible form, with a statement of the purpose for 
data processing attached to that consent. In addition, the 
GDPR states that EU residents will have the right to obtain 
from the data controller (e.g. m-health app developer) 
confirmation as to whether or not their personal data are being 
processed and, if so, where and for what purpose. Further, 
the owner of an app is required to provide a copy of personal 
data upon request, free of charge, in an electronic format, 
and the user has the right to transmit those data to another 
entity (data portability), for example to another health service, 
thereby facilitating the bridge between virtual and actual 
drug treatment service provision for patients and healthcare 
providers. This new EU-wide directive will undoubtedly create 
difficulties for future epidemiological data collection on drug 
use and treatment demands as the number and usage of 
m-health interventions continues to increase. Nevertheless, 
this directive will ensure that, by providing for increased 
transparency and accountability, m-health apps in the drugs 
field can become an essential and secure intervention tool for 
users and professionals across Europe.
I  Conclusions
There is growing interest in the use of m-health apps as 
add-ons to current drug use prevention, harm reduction and 
drug treatment provision systems. The individual, societal 
and economic potential of m-health in general, and in the 
drug use field in particular, is vast. As mobile technologies are 
increasingly available and ever more sophisticated, there is a 
need to further advance the development, quality and usability 
of m-health apps to increase access to drug treatment and 
harm reduction for those in need and reduce general treatment 
costs. Despite the limitations of the methodology used in this 
exercise, we identified a number of initial gaps in the drug use 
field related to m-health applications that can guide future 
investment priorities in this area.
First, there is a clear need to improve the evidence base 
behind the methods applied within drug-related m-health 
applications and their interventions. Currently, the very limited 
evidence base in this field concerns m-health applications with 
alcohol-related interventions. The development of drug-related 
m-health applications may be an attractive endeavour for 
governmental and private agencies, but it would be wrong to 
assume that they do not have the potential to cause harm to 
users. The negative impact of the apps currently downloadable 
to European users and reported here is unknown. With an 
increasing number of such apps developed and available, 
investments in funding research assessing the scientific 
evidence, rather than only the development, of mobile-based 
interventions in the drugs field, should be a priority at EU 
and national levels. In this respect, the development and 
implementation of EU-wide minimum quality standards 
of m-health interventions in the drugs field should also be 
considered. These quality standards, alongside the newly 
adopted EU data protection directives, will ensure safer, more 
transparent, development of digital drug intervention tools 
provided via mobile platforms.
Furthermore, cross-border content relevance of m-health 
interventions appears to be significant, especially between 
world regions. The successful evolution of m-health in the 
European drug use field will therefore rely on the development 
of apps that that are relevant and attractive to European 
citizens and drug use prevention and treatment professionals. 
Cooperation and synergy between EU governments and NGOs 
operating in the prevention and treatment field will therefore be 
crucial. Common core intervention apps with a sound scientific 
evidence base and adapted to national characteristics and 
language are a cost-effective way to increase the availability of 
these tools in Europe.
Another investment priority is the development of m-health 
apps targeting hard-to-reach user groups currently 
underrepresented in the m-health field, such as high-risk drug 
users or MSM. The development of competence-building 
m-health tools for European drug use professionals is another 
investment priority highlighted in this study. A positive 
development in this field will hopefully have an immediate 
positive impact on professional skills, treatment quality and 
overall public health.
Finally, the enormous popularity of smartphone apps as a 
communication tool and trendsetting medium highlights the 
need to develop an EU-wide consensus on effective and safe 
risk communication strategies when communicating drug 
alerts via m-health apps.
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